Resapp Health reports positive results from a US clinical trial in adults with its cough-interpreting smartphone app that diagnoses certain respiratory diseases.
Perth-based Resapp Health, the company that developed an innovative cough-interpreting smartphone app that diagnoses certain respiratory diseases such as pneumonia better than a stethoscope, aims to repeat the success of its West Australian clinical studies in the United States.
Preliminary results from Resapp Health’s first clinical trial in adults conducted at Joondalup Health Campus demonstrated the app was able to diagnose chronic obstructive pulmonary disease (COPD) with 96 percent accuracy, asthma at 92 percent accuracy, and pneumonia at 100 percent accuracy.
In the clinical trial, 322 adults were asked to cough into smartphones and the results were equivalent to the ones of a previous pediatric clinical trial conducted at Joondalup Health Campus and Princess Margaret Hospital in Australia.
According to Tony Keating, ResApp CEO and managing director, two results from the earlier pediatric clinical trials are especially positive.
